AU762128B2 - Agents with an antidepressive effect - Google Patents

Agents with an antidepressive effect Download PDF

Info

Publication number
AU762128B2
AU762128B2 AU50303/99A AU5030399A AU762128B2 AU 762128 B2 AU762128 B2 AU 762128B2 AU 50303/99 A AU50303/99 A AU 50303/99A AU 5030399 A AU5030399 A AU 5030399A AU 762128 B2 AU762128 B2 AU 762128B2
Authority
AU
Australia
Prior art keywords
agent according
pramipexole
sertraline
tetrahydro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50303/99A
Other languages
English (en)
Other versions
AU5030399A (en
Inventor
Jerzy Maj
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of AU5030399A publication Critical patent/AU5030399A/en
Application granted granted Critical
Publication of AU762128B2 publication Critical patent/AU762128B2/en
Assigned to BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG reassignment BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG Request to Amend Deed and Register Assignors: BOEHRINGER INGELHEIM PHARMA KG
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU50303/99A 1998-07-07 1999-07-02 Agents with an antidepressive effect Ceased AU762128B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19830201A DE19830201A1 (de) 1998-07-07 1998-07-07 Mittel mit antidepressiver Wirkung
DE19830201 1998-07-07
PCT/EP1999/004595 WO2000002542A2 (de) 1998-07-07 1999-07-02 Mittel mit antidepressiver wirkung, enthaltend pramipexol und ein weiteres antidepressivum

Publications (2)

Publication Number Publication Date
AU5030399A AU5030399A (en) 2000-02-01
AU762128B2 true AU762128B2 (en) 2003-06-19

Family

ID=7873155

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50303/99A Ceased AU762128B2 (en) 1998-07-07 1999-07-02 Agents with an antidepressive effect

Country Status (32)

Country Link
US (1) US6255329B1 (https=)
EP (1) EP1093369B1 (https=)
JP (1) JP2002520273A (https=)
KR (1) KR100557692B1 (https=)
CN (1) CN1230168C (https=)
AR (1) AR019896A1 (https=)
AT (1) ATE228365T1 (https=)
AU (1) AU762128B2 (https=)
BG (1) BG64972B1 (https=)
BR (1) BR9911768A (https=)
CA (1) CA2336833C (https=)
CZ (1) CZ294087B6 (https=)
DE (2) DE19830201A1 (https=)
DK (1) DK1093369T3 (https=)
EA (1) EA003142B1 (https=)
EE (1) EE04296B1 (https=)
ES (1) ES2183583T3 (https=)
HU (1) HUP0103922A3 (https=)
ID (1) ID27776A (https=)
IL (1) IL140603A0 (https=)
MY (1) MY117969A (https=)
NO (1) NO20010064L (https=)
NZ (1) NZ509729A (https=)
PL (1) PL195043B1 (https=)
PT (1) PT1093369E (https=)
RS (1) RS49795B (https=)
SK (1) SK284923B6 (https=)
TR (1) TR200100146T2 (https=)
TW (1) TW592698B (https=)
WO (1) WO2000002542A2 (https=)
YU (1) YU401A (https=)
ZA (1) ZA200100090B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2301899C (en) * 1998-07-27 2008-11-18 Boehringer Ingelheim Pharma Kg Agent with an antidepressant activity
US20020165246A1 (en) * 2001-03-05 2002-11-07 Andrew Holman Administration of sleep restorative agents
DE10138275A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Verbindungen zur Beseitigung der Anhedonie
US20060281797A1 (en) * 2001-12-11 2006-12-14 University Of Virginia Patent Foundation Neurorestoration with R(+) Pramipexole
ES2432527T3 (es) * 2001-12-11 2013-12-04 University Of Virginia Patent Foundation Uso de pramipexol para tratar la esclerosis lateral amiotrófica
DE10334188B4 (de) * 2003-07-26 2007-07-05 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung von Depressionen
DE10334187A1 (de) * 2003-07-26 2005-03-03 Schwarz Pharma Ag Substituierte 2-Aminotetraline zur Behandlung von Depressionen
CA2554616A1 (en) * 2004-01-22 2005-08-04 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist
ATE444750T1 (de) * 2005-08-15 2009-10-15 Univ Virginia Neurorestauration mit r(+) pramipexol
US8518926B2 (en) 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
ATE537826T1 (de) 2006-05-16 2012-01-15 Knopp Neurosciences Inc Zusammensetzungen aus r(+)- und s(-)-pramipexol sowie verfahren zu ihrer anwendung
US20080254118A1 (en) * 2007-04-11 2008-10-16 Hans-Werner Wernersbach Process for preparing pramipexole dihydrochloride tablets
US8524695B2 (en) 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク． キラル精製置換ベンゾチアゾールジアミンの合成
US20080254117A1 (en) * 2007-04-10 2008-10-16 Noel Cotton Process for preparing pramipexole dihydrochloride tablets
US20110190356A1 (en) * 2008-08-19 2011-08-04 Knopp Neurosciences Inc. Compositions and Methods of Using (R)- Pramipexole
US20100069390A1 (en) 2008-09-05 2010-03-18 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US20120115871A1 (en) * 2009-04-30 2012-05-10 Supemus Pharmaceuticals, Inc Method of treatment of depression
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
ES2950875T3 (es) 2012-02-08 2023-10-16 Supernus Pharmaceuticals Inc Formulaciones de liberación modificada de viloxazina
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3038467B1 (en) 2013-08-13 2020-07-29 Knopp Biosciences LLC Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
IL312486B2 (en) * 2017-04-10 2025-05-01 Chase Therapeutics Corp NK1 antagonist combination and method for treating synucleinopathies
CA3104811C (en) * 2017-06-30 2024-05-28 Chase Therapeutics Corporation Composition comprising pramipexole and nk1-antagonists for treating depression
CN110028464B (zh) * 2019-04-26 2022-11-18 浙江海洋大学 一种南极真菌次级代谢衍生物BTZ-one及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) * 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DE3572485D1 (en) * 1984-12-22 1989-09-28 Thomae Gmbh Dr K Tetrahydro-benzothiazoles, their production and their use as intermediates or drugs
DE3843227A1 (de) * 1988-12-22 1990-07-05 Boehringer Ingelheim Kg Neue verwendung von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzthiazol
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
DE3937271A1 (de) * 1989-11-09 1991-05-16 Boehringer Ingelheim Kg Transdermale applikation von 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzothiazol
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
DE4241013A1 (de) * 1992-12-05 1994-06-09 Boehringer Ingelheim Kg Verwendung von 2-Amino-6-n-propyl-amino-4,5,6,7-tetrahydrobenzothiazol als Arzneimittel mit antidepressiver Wirkung
JP3947582B2 (ja) * 1995-08-15 2007-07-25 中外製薬株式会社 不安神経症治療剤
EA001485B1 (ru) * 1996-03-29 2001-04-23 Пфайзер Инк. Производные бензил(иден)-лактамов, их получение и применение в качестве селективных (ант)агонистов рецепторов 5-htи/или 5-ht
AU734872B2 (en) * 1996-12-02 2001-06-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating movement disorders
WO1999036064A2 (en) * 1998-01-13 1999-07-22 Synchroneuron, Llc Methods of treating tardive dyskinesia and other movement disorders

Also Published As

Publication number Publication date
SK284923B6 (sk) 2006-02-02
PL195043B1 (pl) 2007-08-31
ZA200100090B (en) 2002-04-04
CN1308533A (zh) 2001-08-15
ATE228365T1 (de) 2002-12-15
HUP0103922A3 (en) 2002-08-28
CZ200177A3 (en) 2001-06-13
ES2183583T3 (es) 2003-03-16
CA2336833C (en) 2008-09-23
ID27776A (id) 2001-04-26
DE59903556D1 (de) 2003-01-09
RS49795B (sr) 2008-06-05
US6255329B1 (en) 2001-07-03
KR20010079491A (ko) 2001-08-22
IL140603A0 (en) 2002-02-10
TR200100146T2 (tr) 2001-07-23
EE04296B1 (et) 2004-06-15
WO2000002542A2 (de) 2000-01-20
CZ294087B6 (cs) 2004-10-13
EA200100084A1 (ru) 2001-08-27
PT1093369E (pt) 2003-03-31
BG105112A (bg) 2001-10-31
BG64972B1 (bg) 2006-11-30
KR100557692B1 (ko) 2006-03-07
BR9911768A (pt) 2001-04-03
SK112001A3 (en) 2001-10-08
AU5030399A (en) 2000-02-01
DK1093369T3 (da) 2002-12-16
JP2002520273A (ja) 2002-07-09
AR019896A1 (es) 2002-03-20
PL345842A1 (en) 2002-01-14
NO20010064D0 (no) 2001-01-05
NZ509729A (en) 2003-06-30
MY117969A (en) 2004-08-30
EP1093369B1 (de) 2002-11-27
EE200100014A (et) 2002-06-17
DE19830201A1 (de) 2000-01-13
TW592698B (en) 2004-06-21
CA2336833A1 (en) 2000-01-20
NO20010064L (no) 2001-03-02
HUP0103922A2 (hu) 2002-03-28
EA003142B1 (ru) 2003-02-27
YU401A (sh) 2003-10-31
WO2000002542A3 (de) 2000-06-22
HK1037976A1 (en) 2002-03-01
EP1093369A2 (de) 2001-04-25
CN1230168C (zh) 2005-12-07

Similar Documents

Publication Publication Date Title
AU762128B2 (en) Agents with an antidepressive effect
CA2301899C (en) Agent with an antidepressant activity
JP4796219B2 (ja) 神経保護剤としてのプラミペキソールの使用
JP5263170B2 (ja) 過活動膀胱治療用医薬組成物
HU225534B1 (en) Pharmaceutical compositions comprising mirtazapine and one or more selective serotonin reuptake inhibitors
JP2007517901A (ja) 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
PL196996B1 (pl) Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku
KR20090019765A (ko) 타액 분비 과다증 치료를 위한 알파-2 수용체 작용제(클로니딘) 및 항-무스카린제(옥시부티닌)의 복합물
US6403645B2 (en) Antidepressant effect of norepinephrine uptake 2 inhibitors and combined medications including them
KR930007252B1 (ko) 우울증 치료용 약학조성물
ES2267943T3 (es) Metodos de uso de derivados pirrolicos contra el trastorno obsesivo compulsivo.
US6391876B1 (en) Reboxetine for treatment obsessive compulsive disorders and panic disorder
SK14502000A3 (sk) Kombinácie liekov n. a. r. i. (inhibítorov reaktivácie noradrenalínu), výhodne reboxetínu, a pindololu
WO2002049652A1 (en) Method of treatment
MXPA00012880A (en) Agents with an antidepressive effect
HUP0302752A2 (hu) 2-Amino-1-(4-hidroxi-3-metánszulfonamido-fenil)-etanolt tartalmazó gyógyszerkészítmény és alkalmazása vizeletinkontinencia kezelésére
MXPA00010025A (en) New treatments for nervous disorders
WO2004037238A1 (en) New uses of deramciclane

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)